Investor Relations

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2021

Email Alerts

Receive updates straight into your inbox

Stock Snapshot

Stock Snapshot

Company Overview

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of cancer-targeted immunotherapies and vaccines based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, maveropepimut-S (DPX-Survivac), is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing maveropepimut-S as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. IMV is also developing a DPX-based vaccine to fight against COVID-19.

Investor Contact Information


130 Eileen Stubbs
Suite 19
Dartmouth, Nova Scotia B3B 2C4

Corporate Office

2875 Boulevard Laurier
Delta 1, Suite 220
Québec, Québec G1V 2M2

Investor Relations

Transfer Agent

Computershare Investor Services Inc.